Use of Regorafenib in Recurrent Epithelial Ovarian Cancer

NCT02736305 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Neoplasms

Interventions

DRUG: Regorafenib

Sponsor

National Cancer Centre, Singapore